Market Cap	1.64M 1.43M 1.33M 1.24M 2.32M 155M 2.34M 15.76M 6.13M 76.22M 6.16M 6.03M 265M	P/E 2007	-0.73x	P/E 2008	-2.06x
Enterprise Value	8.13M 7.1M 6.57M 6.13M 11.51M 768M 11.6M 78.08M 30.38M 378M 30.52M 29.86M 1.31B	EV / Sales 2007	1.81x	EV / Sales 2008	0.6x
Free-Float	95.75%	Yield 2007 *	-	Yield 2008	-

* Estimated data More valuation ratios

Press Releases: Synovics Pharmaceuticals, Inc.

30/11/-1	SYNOVICS PHARMA IN COM USD0.001 : Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer	PR
30/11/-1	SYNOVICS PHARMA IN COM USD0.001 : Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract	PR
30/11/-1	SYNOVICS PHARMA IN COM USD0.001 : ceuticals Announces Continued Growth of Customer Relationships	PR
30/11/-1	SYNOVICS PHARMA IN COM USD0.001 : ceuticals Files Its Second Quarter, 2008 Form 10Q with the SEC	PR
30/11/-1	SYNOVICS PHARMA IN COM USD0.001 : ceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals	PR

More press releases

Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Companyâ€™s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.

Employees

Sector

Pharmaceuticals

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNOVICS PHARMACEUTICALS, INC.	-99.50%	-.--%	-	-	3.65K
ELI LILLY AND COMPANY	+0.32%	-2.41%	+44.49%	+140.80%	980B
JOHNSON & JOHNSON	+1.27%	-1.85%	+54.41%	+39.65%	550B
ABBVIE INC.	+6.25%	+3.80%	+24.13%	+67.39%	382B
ROCHE HOLDING AG	+0.25%	-1.93%	+23.33%	+16.35%	316B
ASTRAZENECA PLC	+0.42%	+0.68%	+27.89%	+14.57%	272B
NOVARTIS AG	+1.67%	+0.05%	+26.76%	+33.56%	268B
NOVO NORDISK A/S	+2.39%	+5.02%	-36.96%	-44.76%	199B
AMGEN INC.	+2.11%	-1.66%	+19.14%	+50.10%	182B
GILEAD SCIENCES, INC.	+0.90%	+0.46%	+15.09%	+59.86%	154B
Average	-8.39%	-1.61%	+22.03%	+41.95%	366.93B
Weighted average by Cap.	+1.53%	-2.66%	+31.28%	+64.51%

	2007	2008
Net sales	23.47M 20.5M 18.97M 17.7M 33.23M 2.22B 33.48M 225M 87.7M 1.09B 88.1M 86.19M 3.79B	25.96M 22.68M 20.98M 19.58M 36.76M 2.45B 37.03M 249M 97.01M 1.21B 97.47M 95.35M 4.19B
Net income	-20.86M -18.23M -16.86M -15.74M -29.54M -1.97B -29.76M -200M -77.95M -969M -78.31M -76.61M -3.37B	-4.01M -3.5M -3.24M -3.02M -5.67M -379M -5.71M -38.47M -14.97M -186M -15.04M -14.71M -647M
Net Debt	18.79M 16.42M 15.19M 14.18M 26.61M 1.78B 26.81M 180M 70.22M 873M 70.55M 69.02M 3.03B	6.49M 5.67M 5.24M 4.89M 9.19M 613M 9.26M 62.32M 24.25M 301M 24.36M 23.83M 1.05B

Synovics Pharmaceuticals, Inc. Stock Other OTC

Stocks

SYVC

US87163M1018

Pharmaceuticals

Valuation: Synovics Pharmaceuticals, Inc.

Press Releases: Synovics Pharmaceuticals, Inc.

Quotes and Performance

Other Pharmaceuticals

Financials

Company Profile